Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - xarelto
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpfebe758b815af2dff26af1acacd31f32
identifier: http://ema.europa.eu/identifier
/EU/1/08/472/025-035, EU/1/08/472/041, EU/1/08/472/046-047
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Xarelto 2.5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-febe758b815af2dff26af1acacd31f32
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/08/472/025-035, EU/1/08/472/041, EU/1/08/472/046-047
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - xarelto
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
You have been given Xarelto because
or
Xarelto contains the active substance rivaroxaban and belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.
Do not take Xarelto
Warnings and precautions Talk to your doctor or pharmacist before taking Xarelto. Xarelto should not be used in combination with certain other medicines which reduce blood clotting such as prasugrel or ticagrelor other than acetylsalicylic acid and clopidogrel/ticlopidine.
Take special care with Xarelto
severe kidney disease, since your kidney function may affect the amount of medicine that works in your body
if you are taking other medicines to prevent blood clotting (e.g. warfarin, dabigatran, apixaban or heparin), when changing anticoagulant treatment or while getting heparin through a venous or arterial line to keep it open (see section Other medicines and Xarelto )
bleeding disorders
very high blood pressure, not controlled by medical treatment
diseases of your stomach or bowel that might result in bleeding, e.g. inflammation of the bowels or stomach, or inflammation of the oesophagus (gullet), e.g. due to gastroesophageal reflux disease (disease where stomach acid goes upwards into the oesophagus) or tumours located in the stomach or bowels or genital tract or urinary tract
a problem with the blood vessels in the back of your eyes (retinopathy)
a lung disease where your bronchi are widened and filled with pus (bronchiectasis), or previous bleeding from your lung
you are older than 75 years
you weigh less than 60 kg
you have a coronary artery disease with severe symptomatic heart failure
If any of the above apply to you, tell your doctor before you take Xarelto. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.
If you need to have an operation
it is very important to take Xarelto before and after the injection or removal of the catheter exactly at the times you have been told by your doctor
tell your doctor immediately if you get numbness or weakness of your legs or problems with your bowel or bladder after the end of anaesthesia, because urgent care is necessary.
Children and adolescents Xarelto 2.5 mg tablets are not recommended for people under 18 years of age. There is not enough information on their use in children and adolescents.
Other medicines and Xarelto Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
some medicines for fungal infections (e.g. fluconazole, itraconazole, voriconazole, posaconazole), unless they are only applied to the skin
ketoconazole tablets (used to treat Cushing s syndrome - when the body produces an excess of cortisol)
some medicines for bacterial infections (e.g. clarithromycin, erythromycin)
some anti-viral medicines for HIV / AIDS (e.g. ritonavir)
other medicines to reduce blood clotting (e.g. enoxaparin, clopidogrel or vitamin K antagonists such as warfarin and acenocoumarol, prasugrel and ticagrelor (see section Warnings and Precautions ))
anti-inflammatory and pain relieving medicines (e.g. naproxen or acetylsalicylic acid)
dronedarone, a medicine to treat abnormal heart beat
some medicines to treat depression (selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs))
If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.
If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.
some medicines for treatment of epilepsy (phenytoin, carbamazepine, phenobarbital)
St John s Wort (Hypericum perforatum), a herbal product used for depression
rifampicin, an antibiotic If any of the above apply to you, tell your doctor before taking Xarelto, because the effect of Xarelto may be reduced. Your doctor will decide, if you should be treated with Xarelto and if you should be kept under closer observation.
Pregnancy and breast---feeding Do not take Xarelto if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Xarelto. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.
Driving and using machines Xarelto may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4, Possible side effects ). You should not drive, ride a bicycle or use any tools or machines if you are affected by these symptoms.
Xarelto contains lactose and sodium If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How much to take The recommended dose is one 2.5 mg tablet twice a day. Take Xarelto around the same time every day (for example, one tablet in the morning and one in the evening). This medicine can be taken with or without food.
If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Xarelto. The tablet may be crushed and mixed with water or apple puree immediately before you take it.
If necessary, your doctor may also give you the crushed Xarelto tablet through a stomach tube.
Xarelto will not be given to you on its own. Your doctor will also tell you to take acetylsalicylic acid.
If you get Xarelto after an acute coronary syndrome, your doctor may tell you to also take clopidogrel or ticlopidine. If you get Xarelto after a procedure to open a narrowed or closed artery of your leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to acetylsalicylic acid for a short while.
Your doctor will tell you how much of these to take (usually between 75 to 100 mg acetylsalicylic acid daily or a daily dose of 75 to 100 mg acetylsalicylic acid plus a daily dose of either 75 mg clopidogrel or a standard daily dose of ticlopidine).
When to start Xarelto Treatment with Xarelto after an acute coronary syndrome should be started as soon as possible after stabilisation of the acute coronary syndrome, at the earliest 24 hours after admission to hospital and at the time when parenteral (via injection) anticoagulation therapy would normally be stopped. Your doctor will tell you when to start treatment with Xarelto if you have been diagnosed with coronary artery disease or peripheral artery disease. Your doctor will decide how long you must continue treatment.
If you take more Xarelto than you should Contact your doctor immediately if you have taken too many Xarelto tablets. Taking too much Xarelto increases the risk of bleeding.
If you forget to take Xarelto
Do not take a double dose to make up for a missed dose. If you miss a dose, take your next dose at the usual time.
If you stop taking Xarelto Take Xarelto on a regular basis and for as long as your doctor keeps prescribing it.
Do not stop taking Xarelto without talking to your doctor first. If you stop taking this medicine, it may increase your risk of having another heart attack or stroke or dying from a disease related to your heart or your blood vessels.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Xarelto can cause side effects, although not everybody gets them.
Like other similar medicines to reduce the formation of blood clots, Xarelto may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.
Tell your doctor immediately if you experience any of the following side effects:
Your doctor may decide to keep you under closer observation or change the treatment.
Overall list of possible side effects
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Not known (frequency cannot be estimated from the available data)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Crushed tablets Crushed tablets are stable in water or apple puree for up tp 4 hours.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Xarelto contains
in bottles of 100 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Bayer AG 51368 Leverkusen Germany
Manufacturer
The manufacturer can be identified by the batch number printed on the side flap of the carton and on each blister or bottle:
If the first and second characters are BX, the manufacturer is
Bayer AG
Kaiser-Wilhelm-Allee
51368 Leverkusen
Germany
If the first and second characters are IT, the manufacturer is
Bayer HealthCare Manufacturing Srl.
Via delle Groane, 20024 Garbagnate Milanese
Italy
If the first and second characters are BT, the manufacturer is
Bayer Bitterfeld GmbH
Ortsteil Greppin, Salegaster Chaussee 1
06803 Bitterfeld-Wolfen
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi / Belgique / Belgien Bayer SA-NV T l/Tel: +32-(0)2-535 63 Lietuva UAB Bayer Tel: +370-5-233 68
: +359-(0)2-424 72 Luxembourg / Luxemburg Bayer SA-NV T l/Tel: +32-(0)2-535 63 esk republika Bayer s.r.o. Tel: +420-266 101 Magyarorsz g Bayer Hung ria KFT Tel: +36-1-487 4Danmark Bayer A/S Tlf: +45-45 235 Malta Alfred Gera and Sons Ltd. Tel: +356-21 44 62 Deutschland Bayer Vital GmbH Tel: +49-(0)214-30 513 Nederland Bayer B.V. Tel: +31-23-799 1Eesti Bayer O
Tel: +372-655 85 Norge Bayer AS Tlf: +47-23 13 05
Bayer
: +30-210-618 75 sterreich Bayer Austria Ges. m. b. H. Tel: +43-(0)1-711 Espa a Bayer Hispania S.L. Tel: +34-93-495 65 Polska Bayer Sp. z o.o. Tel: +48-22-572 35 France Bayer HealthCare T l (N vert): +33-(0)800 87 54 Portugal Bayer Portugal, Lda. Tel: +351-21-416 42 Hrvatska Bayer d.o.o. Tel: + 385-(0)1-6599 Rom nia SC Bayer SRL
Tel: +40-(0)21-529 59 Ireland Bayer Limited Tel: +353 1 216 3Slovenija Bayer d. o. o. Tel: +386-(0)1-58 14 sland Icepharma hf. S mi: +354-540 80 Slovensk republika Bayer, spol. s r.o. Tel: +421-(0)2-59 21 31 Italia Bayer S.p.A. Tel: +39-02-3978 1
Suomi/Finland Bayer Oy Puh/Tel: +358-(0)20-78
NOVAGEM Limited : +357-22-48 38 Sverige Bayer AB Tel: +46-(0)8-580 223 Latvija SIA Bayer Tel: +371-67 84 55 United Kingdom (Northern Ireland) Bayer AG Tel: +44-(0) 118 206 3This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.
Package leaflet: Information for the user
Xarelto 10 mg film-coated tablets rivaroxaban
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
What is in this leaflet
Entry 1 - fullUrl = Composition/composition-en-febe758b815af2dff26af1acacd31f32
Resource Composition:
Generated Narrative: Composition composition-en-febe758b815af2dff26af1acacd31f32
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/08/472/025-035, EU/1/08/472/041, EU/1/08/472/046-047status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - xarelto
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpfebe758b815af2dff26af1acacd31f32
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpfebe758b815af2dff26af1acacd31f32
identifier:
http://ema.europa.eu/identifier
/EU/1/08/472/025-035, EU/1/08/472/041, EU/1/08/472/046-047type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Xarelto 2.5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en